Aquestive Therapeutics Inc

10-Year Study

AQST.US · Healthcare · US · Common Stock

Executive Summary: Aquestive Therapeutics Inc has compounded at -15.0% annually over the last 10 years, with a maximum drawdown of 96.4% and an annualized volatility of 163.2%.

1Y CAGR
+63.7%
3Y CAGR
+23.3%
5Y CAGR
+2.9%
10Y CAGR
-15.0%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
96.4%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
0.32
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
0.70
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
103.9%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2023 · +123.9%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2022 · -76.8%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
38%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
2026-54.335.63.82.7————————-34.1%
2025-15.2-7.33.60.9-7.422.116.0-1.848.322.0-9.24.481.5%
202418.353.616.1-21.1-14.3-9.747.718.09.910.2-7.3-30.176.2%
2023-1.3-12.145.717.572.4-28.632.7-25.1-6.72.643.3-10.2123.9%
2022-30.12.6-6.5-46.4-29.0-35.628.575.8-19.0-25.66.7-2.8-76.8%
2021-1.1-13.413.5-21.7-8.87.0-18.140.9-4.817.914.8-34.1-27.3%
2020-30.4-7.9-41.396.813.0-0.28.249.4-38.2-0.345.9-24.2-8.1%
2019-2.731.3-14.2-17.4-34.912.9-18.811.4-16.320.8102.9-25.3-7.6%
2018———————19.7-2.8-13.6-43.2-26.7-58.1%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 163.2%. The dominant macroeconomic risk driver is SHV.US, accounting for 52.7% of variance. Idiosyncratic stock-specific factors contribute 18.1%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2018-07-0110000
2018-08-0111974.734042553193
2018-09-0111642.287234042555
2018-10-0110059.840425531916
2018-11-015711.436170212766
2018-12-014188.829787234043
2019-01-014075.797872340426
2019-02-015352.393617021277
2019-03-014594.414893617021
2019-04-013796.54255319149
2019-05-012473.4042553191493
2019-06-012792.553191489362
2019-07-012267.2872340425533
2019-08-012526.595744680851
2019-09-012114.3617021276596
2019-10-012553.1914893617018
2019-11-015179.521276595746
2019-12-013869.6808510638302
2020-01-012692.81914893617
2020-02-012480.053191489362
2020-03-011456.1170212765958
2020-04-012865.6914893617018
2020-05-013238.031914893617
2020-06-013231.3829787234044
2020-07-013497.340425531915
2020-08-015226.063829787234
2020-09-013228.0585106382982
2020-10-013218.085106382979
2020-11-014694.148936170212
2020-12-013557.18085106383
2021-01-013517.2872340425533
2021-02-013045.2127659574467
2021-03-013457.4468085106387
2021-04-012706.117021276596
2021-05-012466.7553191489365
2021-06-012639.6276595744685
2021-07-012160.904255319149
2021-08-013045.2127659574467
2021-09-012898.9361702127662
2021-10-013417.5531914893613
2021-11-013922.8723404255325
2021-12-012586.4361702127662
2022-01-011808.5106382978724
2022-02-011855.0531914893618
2022-03-011735.372340425532
2022-04-01930.8510638297872
2022-05-01660.904255319149
2022-06-01425.39893617021283
2022-07-01546.5425531914893
2022-08-01960.7712765957448
2022-09-01777.9255319148937
2022-10-01578.4574468085107
2022-11-01617.0212765957448
2022-12-01599.8005319148937
2023-01-01591.7553191489362
2023-02-01520.279255319149
2023-03-01757.9787234042552
2023-04-01890.9574468085108
2023-05-011535.9042553191491
2023-06-011097.0744680851064
2023-07-011456.1170212765958
2023-08-011090.4255319148936
2023-09-011017.2872340425533
2023-10-011043.8829787234044
2023-11-011496.0106382978724
2023-12-011343.085106382979
2024-01-011589.0957446808513
2024-02-012440.1595744680853
2024-03-012832.4468085106387
2024-04-012234.0425531914893
2024-05-011914.8936170212767
2024-06-011728.7234042553193
2024-07-012553.1914893617018
2024-08-013011.9680851063836
2024-09-013311.1702127659582
2024-10-013650.265957446809
2024-11-013384.3085106382982
2024-12-012367.021276595745
2025-01-012007.9787234042553
2025-02-011861.7021276595744
2025-03-011928.1914893617022
2025-04-011944.8138297872342
2025-05-011801.8617021276598
2025-06-012200.797872340426
2025-07-012553.1914893617018
2025-08-012506.648936170213
2025-09-013716.755319148936
2025-10-014534.574468085107
2025-11-014115.691489361702
2025-12-014295.212765957447
2026-01-011961.4361702127662
2026-02-012659.574468085106
2026-03-012759.3085106382982
2026-04-012832.4468085106387
Annual Return Matrix
YearAnnual Return
2019-0.07619047619047614
2020-0.08075601374570462
2021-0.2728971962616822
2022-0.7680976863753213
20231.2392195987141115
20240.7623762376237624
20250.8146067415730336
2026-0.3405572755417957
Total Factor Risk
1.632090865385097
VTI.US Exposure
0.22758649116406815
VEA.US Exposure
0.0054995409169244554
VWO.US Exposure
-0.006890989174942859
QQQ.US Exposure
-0.025003417005177546
VTV.US Exposure
-0.0051096273269518825
IJR.US Exposure
-0.006879182437834985
QUAL.US Exposure
-0.0086764544122841
SHV.US Exposure
0.5268446079072263
TLT.US Exposure
-0.007926079541621103
LQD.US Exposure
0.08501594775035264
HYG.US Exposure
0.023488899625386108
GLD.US Exposure
0.006539305416191654
USO.US Exposure
-0.0007714037060151644
VNQ.US Exposure
0.005090438308988587
BTC-USD.CC Exposure
0.0014238110003021674
CPER.US Exposure
0.002552669118461452
VIX.INDX Exposure
-0.002179634780744886
UUP.US Exposure
-0.0004986364864441878
TIP.US Exposure
-0.0008995957136956666
Idiosyncratic Exposure
0.1807933093778108
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
163.2%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Market Cap$504.0M
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators relative to key technical levels: distance from 50-Day SMA (intermediate trend), 200-Day SMA (long-term trend), 52-Week High (bullish proximity), and Beta (market sensitivity coefficient).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+4.7%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
-12.1%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
43.1% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
1.53
Market sensitivity coefficient

Frequently Asked Questions & Methodology

Is Aquestive Therapeutics Inc a high-risk investment?

Aquestive Therapeutics Inc (AQST.US) has an annualized volatility of 163.2% and experienced a maximum drawdown of 96.4% over the last 10 years. Its primary macro risk driver is SHV.US.

What is the 10-year return of AQST.US?

Over the past 10 years, AQST.US has generated a Compound Annual Growth Rate (CAGR) of -15.0%. It has had a positive return in 38% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on Aquestive Therapeutics Inc

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest